<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066937</url>
  </required_header>
  <id_info>
    <org_study_id>RPN 00-03-21-02</org_study_id>
    <secondary_id>R01DE013906</secondary_id>
    <nct_id>NCT00066937</nct_id>
  </id_info>
  <brief_title>Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD)</brief_title>
  <official_title>Pain Management in Temporomandibular Joint Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Dental and Craniofacial Research (NIDCR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the combination of cognitive-behavioral
      treatment and nortriptyline are more effective than each treatment alone in reducing the pain
      and disability associated with TMD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled trial evaluating pharmacological (nortriptyline vs. active
      placebo - benztropine) and psychological (cognitive-behavioral therapy vs. disease education)
      treatments for pain and disability due to temporomandibular joint disorder (TMD). Patients 18
      to 65 years old meeting RDC criteria for TMD and other eligibility criteria complete a 3-week
      baseline monitoring phase prior to randomization. Active treatment consists of weekly visits
      for 8 week, then maintenance treatment for 6 months. Outcome measures include pain, physical
      and psychosocial function and are assessed at post-treatment, 3-months, and 6-months
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Pain</measure>
    <time_frame>baseline, post-treatment, 3 months, 6 months</time_frame>
    <description>0 (no pain) to 10 (pain as bad as could be) rating of average pain during the past week; higher scores indicate greater pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Pain-related Interference</measure>
    <time_frame>baseline, post-treatment, 3 months, 6 months</time_frame>
    <description>Multidimensional Pain Inventory: Pain interference subscale score; average score computed from 12 items rated on scale from 0=no interference to 6=extreme interference; higher scores indicate greater pain-related interference</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Worst Pain</measure>
    <time_frame>baseline, post-treatment, 3 months, 6 months</time_frame>
    <description>0 (no pain) to 10 (pain as bad as could be) rating of worst pain during the past week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental Health as Assessed by the Short Form 36 Healthy Survey</measure>
    <time_frame>baseline, post-treatment, 3 months, 6 months</time_frame>
    <description>The Mental Health Component score from the Short Form (36) Health Survey, which is a 36-item, patient-reported survey of patient health. The mental health component score is calculated from responses to the general health, mental health, vitality, physical and emotional role limitations, and social functioning subscales, with higher scores indicating better mental health. The scale ranges from zero (equivalent to maximum disability) to 100 (no disability).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Temporomandibular Joint Disorders</condition>
  <arm_group>
    <arm_group_label>Nortriptyline Oral Capsule/CBT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of CBT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benztropine Oral Product/CBT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of CBT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nortriptyline Oral Capsule/Disease MGT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of TMD disease management.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benztropine Oral Product/Disease MGT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of TMD disease management.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nortriptyline Oral Capsule</intervention_name>
    <description>Nortriptyline will be titrated up from 25 mg qhs to a maximum dose of 150 mg qhs based on treatment response and side effect profile.</description>
    <arm_group_label>Nortriptyline Oral Capsule/CBT</arm_group_label>
    <arm_group_label>Nortriptyline Oral Capsule/Disease MGT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benztropine Oral Product</intervention_name>
    <description>Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile.</description>
    <arm_group_label>Benztropine Oral Product/CBT</arm_group_label>
    <arm_group_label>Benztropine Oral Product/Disease MGT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CBT</intervention_name>
    <description>Six in-person, individual sessions of cognitive-behavioral therapy for pain management include relaxation training, pain coping skills training, cognitive therapy for negative and dysfunctional thoughts, and diaries for monitoring relaxation, goals, and negative thinking.</description>
    <arm_group_label>Nortriptyline Oral Capsule/CBT</arm_group_label>
    <arm_group_label>Benztropine Oral Product/CBT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Disease MGT</intervention_name>
    <description>Six in-person, individual sessions of temporomandibular joint disorder (TMD) disease management (MGT) that include information about the jaw and good oral habits, diet, sleep, and general stress management.</description>
    <arm_group_label>Nortriptyline Oral Capsule/Disease MGT</arm_group_label>
    <arm_group_label>Benztropine Oral Product/Disease MGT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Age &gt;= 18 and &lt;= 65

          -  Pain &gt;= 3 months duration due to temporomandibular joint disorder

          -  Pain due to TMD is primary if other pain conditions present

        Exclusion:

          -  Continuous, chronic painful non-reducing disc displacement of TMJ and patient can't
             open mouth

          -  Unstable or acute severe pain from another pain condition

          -  Patient is pregnant

          -  Presence of a medical condition that contraindicates nortriptyline: angle-closure
             glaucoma,symptomatic orthosis

          -  EKG: first degree heart block or QTc &gt; 450 msec

          -  Unstable angina or a history of a myocardial infarction within the past 3 months

          -  Current treatment with an antidepressant which cannot be withdrawn

          -  Current use of a medication that interacts with nortriptyline to raise blood levels,
             such as selective serotonin reuptake inhibitors (e.g.,paroxetine), systemic
             anti-fungal agents (fluconazole), antiarrhythmics (e.g., quinidine), antipsychotics
             (e.g., haloperidol), and antibiotics (e.g., erythromycin).

          -  Presence of dementia, psychosis or other disorder of cognition that impairs ability to
             participate in minimal contact intervention

          -  Beck Depression Inventory (BDI) score &gt;= 35 OR BDI Item #9 (suicide item) is scored &gt;
             1

          -  Patient has a terminal illness with a life expectancy of less than six months

          -  History of arthrotomy of temporomandibular joint

          -  History of allergic reaction to nortriptyline or benztropine

          -  History of a therapeutic trial with nortriptyline (dose &gt;= 100 mg for at least 3
             weeks)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer A Haythornthwaite, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland, Dental School</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2003</study_first_submitted>
  <study_first_submitted_qc>August 7, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2003</study_first_posted>
  <results_first_submitted>April 17, 2017</results_first_submitted>
  <results_first_submitted_qc>July 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 24, 2017</results_first_posted>
  <last_update_submitted>July 21, 2017</last_update_submitted>
  <last_update_submitted_qc>July 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Temporomandibular Joint Disorders</mesh_term>
    <mesh_term>Temporomandibular Joint Dysfunction Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nortriptyline</mesh_term>
    <mesh_term>Benztropine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nortriptyline Oral Capsule/CBT</title>
          <description>Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of CBT.</description>
        </group>
        <group group_id="P2">
          <title>Benztropine Oral Product/CBT</title>
          <description>Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of CBT.</description>
        </group>
        <group group_id="P3">
          <title>Nortriptyline Oral Capsule/Disease MGT</title>
          <description>Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of TMD disease management.</description>
        </group>
        <group group_id="P4">
          <title>Benztropine Oral Product/Disease MGT</title>
          <description>Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of TMD disease management.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>3 Month Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>6 Month Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nortriptyline Oral Capsule/CBT</title>
          <description>Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of CBT.</description>
        </group>
        <group group_id="B2">
          <title>Benztropine Oral Product/CBT</title>
          <description>Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of CBT.</description>
        </group>
        <group group_id="B3">
          <title>Nortriptyline Oral Capsule/Disease MGT</title>
          <description>Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of TMD disease management.</description>
        </group>
        <group group_id="B4">
          <title>Benztropine Oral Product/Disease MGT</title>
          <description>Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of TMD disease management.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="37"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.7" spread="12.0"/>
                    <measurement group_id="B2" value="38.4" spread="12.5"/>
                    <measurement group_id="B3" value="37.2" spread="11.5"/>
                    <measurement group_id="B4" value="33.3" spread="11.3"/>
                    <measurement group_id="B5" value="36.4" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Pain</title>
        <description>0 (no pain) to 10 (pain as bad as could be) rating of average pain during the past week; higher scores indicate greater pain</description>
        <time_frame>baseline, post-treatment, 3 months, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nortriptyline Oral Capsule/CBT</title>
            <description>Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of CBT.</description>
          </group>
          <group group_id="O2">
            <title>Benztropine Oral Product/CBT</title>
            <description>Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of CBT.</description>
          </group>
          <group group_id="O3">
            <title>Nortriptyline Oral Capsule/Disease MGT</title>
            <description>Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of TMD disease management.</description>
          </group>
          <group group_id="O4">
            <title>Benztropine Oral Product/Disease MGT</title>
            <description>Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of TMD disease management.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Pain</title>
          <description>0 (no pain) to 10 (pain as bad as could be) rating of average pain during the past week; higher scores indicate greater pain</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="2.2"/>
                    <measurement group_id="O2" value="4.4" spread="2.1"/>
                    <measurement group_id="O3" value="4.5" spread="2.2"/>
                    <measurement group_id="O4" value="5.0" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.6"/>
                    <measurement group_id="O2" value="2.7" spread="2.1"/>
                    <measurement group_id="O3" value="2.0" spread="1.4"/>
                    <measurement group_id="O4" value="2.8" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.6"/>
                    <measurement group_id="O2" value="2.4" spread="2.2"/>
                    <measurement group_id="O3" value="2.2" spread="2.1"/>
                    <measurement group_id="O4" value="2.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.7"/>
                    <measurement group_id="O2" value="2.0" spread="2.1"/>
                    <measurement group_id="O3" value="1.4" spread="1.6"/>
                    <measurement group_id="O4" value="2.2" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVAs compared baseline to each timepoint</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain-related Interference</title>
        <description>Multidimensional Pain Inventory: Pain interference subscale score; average score computed from 12 items rated on scale from 0=no interference to 6=extreme interference; higher scores indicate greater pain-related interference</description>
        <time_frame>baseline, post-treatment, 3 months, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nortriptyline Oral Capsule/CBT</title>
            <description>Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of CBT.</description>
          </group>
          <group group_id="O2">
            <title>Benztropine Oral Product/CBT</title>
            <description>Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of CBT.</description>
          </group>
          <group group_id="O3">
            <title>Nortriptyline Oral Capsule/Disease MGT</title>
            <description>Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of TMD disease management.</description>
          </group>
          <group group_id="O4">
            <title>Benztropine Oral Product/Disease MGT</title>
            <description>Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of TMD disease management.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain-related Interference</title>
          <description>Multidimensional Pain Inventory: Pain interference subscale score; average score computed from 12 items rated on scale from 0=no interference to 6=extreme interference; higher scores indicate greater pain-related interference</description>
          <units>Change in scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in score from baseline to post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.9"/>
                    <measurement group_id="O2" value="0.5" spread="0.9"/>
                    <measurement group_id="O3" value="0.5" spread="0.7"/>
                    <measurement group_id="O4" value="1.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in score from baseline to 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.9"/>
                    <measurement group_id="O2" value="0.8" spread="0.9"/>
                    <measurement group_id="O3" value="1.0" spread="0.9"/>
                    <measurement group_id="O4" value="1.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in score from baseline to 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.8"/>
                    <measurement group_id="O2" value="0.7" spread="1.2"/>
                    <measurement group_id="O3" value="0.7" spread="0.8"/>
                    <measurement group_id="O4" value="0.8" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVAs compared baseline scores to each period of follow-up (post-treatment, 3-months, 6 months)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Worst Pain</title>
        <description>0 (no pain) to 10 (pain as bad as could be) rating of worst pain during the past week</description>
        <time_frame>baseline, post-treatment, 3 months, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nortriptyline Oral Capsule/CBT</title>
            <description>Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of CBT.</description>
          </group>
          <group group_id="O2">
            <title>Benztropine Oral Product/CBT</title>
            <description>Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of CBT.</description>
          </group>
          <group group_id="O3">
            <title>Nortriptyline Oral Capsule/Disease MGT</title>
            <description>Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of TMD disease management.</description>
          </group>
          <group group_id="O4">
            <title>Benztropine Oral Product/Disease MGT</title>
            <description>Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of TMD disease management.</description>
          </group>
        </group_list>
        <measure>
          <title>Worst Pain</title>
          <description>0 (no pain) to 10 (pain as bad as could be) rating of worst pain during the past week</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="2.3"/>
                    <measurement group_id="O2" value="6.1" spread="2.2"/>
                    <measurement group_id="O3" value="6.3" spread="2.4"/>
                    <measurement group_id="O4" value="7.2" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="2.9"/>
                    <measurement group_id="O2" value="4.1" spread="2.8"/>
                    <measurement group_id="O3" value="3.2" spread="2.1"/>
                    <measurement group_id="O4" value="4.4" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="2.4"/>
                    <measurement group_id="O2" value="3.3" spread="2.3"/>
                    <measurement group_id="O3" value="3.4" spread="2.7"/>
                    <measurement group_id="O4" value="4.1" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="2.1"/>
                    <measurement group_id="O2" value="3.1" spread="2.7"/>
                    <measurement group_id="O3" value="2.7" spread="2.2"/>
                    <measurement group_id="O4" value="3.4" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVAs compared baseline scores to each period of follow-up (post-treatment, 3-months, 6 months)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mental Health as Assessed by the Short Form 36 Healthy Survey</title>
        <description>The Mental Health Component score from the Short Form (36) Health Survey, which is a 36-item, patient-reported survey of patient health. The mental health component score is calculated from responses to the general health, mental health, vitality, physical and emotional role limitations, and social functioning subscales, with higher scores indicating better mental health. The scale ranges from zero (equivalent to maximum disability) to 100 (no disability).</description>
        <time_frame>baseline, post-treatment, 3 months, 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nortriptyline Oral Capsule/CBT</title>
            <description>Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of CBT.</description>
          </group>
          <group group_id="O2">
            <title>Benztropine Oral Product/CBT</title>
            <description>Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of CBT.</description>
          </group>
          <group group_id="O3">
            <title>Nortriptyline Oral Capsule/Disease MGT</title>
            <description>Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of TMD disease management.</description>
          </group>
          <group group_id="O4">
            <title>Benztropine Oral Product/Disease MGT</title>
            <description>Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of TMD disease management.</description>
          </group>
        </group_list>
        <measure>
          <title>Mental Health as Assessed by the Short Form 36 Healthy Survey</title>
          <description>The Mental Health Component score from the Short Form (36) Health Survey, which is a 36-item, patient-reported survey of patient health. The mental health component score is calculated from responses to the general health, mental health, vitality, physical and emotional role limitations, and social functioning subscales, with higher scores indicating better mental health. The scale ranges from zero (equivalent to maximum disability) to 100 (no disability).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" spread="8.1"/>
                    <measurement group_id="O2" value="49.2" spread="9.3"/>
                    <measurement group_id="O3" value="51.2" spread="8.8"/>
                    <measurement group_id="O4" value="48.0" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" spread="10.4"/>
                    <measurement group_id="O2" value="48.4" spread="8.1"/>
                    <measurement group_id="O3" value="52.6" spread="10.0"/>
                    <measurement group_id="O4" value="53.3" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" spread="8.9"/>
                    <measurement group_id="O2" value="50.2" spread="8.7"/>
                    <measurement group_id="O3" value="52.6" spread="10.0"/>
                    <measurement group_id="O4" value="53.8" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2" spread="7.8"/>
                    <measurement group_id="O2" value="53.3" spread="12.8"/>
                    <measurement group_id="O3" value="52.3" spread="7.2"/>
                    <measurement group_id="O4" value="53.6" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVAs compared baseline scores to each period of follow-up (post-treatment, 3-months, 6 months)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected weekly during the treatment phase, then at 3- and 6-months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nortriptyline Oral Capsule/CBT</title>
          <description>Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of CBT.</description>
        </group>
        <group group_id="E2">
          <title>Benztropine Oral Product/CBT</title>
          <description>Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of CBT.</description>
        </group>
        <group group_id="E3">
          <title>Nortriptyline Oral Capsule/Disease MGT</title>
          <description>Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of TMD disease management.</description>
        </group>
        <group group_id="E4">
          <title>Benztropine Oral Product/Disease MGT</title>
          <description>Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of TMD disease management.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>drymouth</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>sedation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Haythornthwaite</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-550-7985</phone>
      <email>jhaytho1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

